Here are the 25 drugs most often administered in outpatient settings, followed by percentage of outpatient encounters:
- Triamcinolone acetonide, injection, 10mg: 12.3 percent
- Dexamethasone sodium phosphate, injection, 1mg: 8.1 percent
- Vitamin B-12 injection, 1,000mcg: 4.2 percent
- Ketorolac tromethamine, injection, 15mg: 3.8 percent
- Alfibercept, injection, 1mg: 3.7 percent
- Betamethasone acetate and betamethasone sodium phosphate, injection, 3 mg: 3.4 percent
- Ceftriaxone sodium, injection, 250mg: 3.2 percent
- Methylprednisolone acetate, injection, 40mg: 3.2 percent
- Bevacizumab, injection, 10mg: 2.9 percent
- Unclassified drugs, injection: 2.4 percent
- Testosterone cypionate, injection, 1mg: 2.2 percent
- Methylprednisolone acetate, injection, 80mg: 2.1 percent
- Medroxyprogesterone acetate, injection, 1mg: 1.7 percent
- Diphenhydramine HCL, injection, 50mg: 1.6 percent
- Regadenoson, injection, 0.1mg: 1.6 percent
- OnabotulinumtoxinA, injection, 1 unit: 1.5 percent
- Normal saline solution, infusion, 1,000cc: 1.4 percent
- Normal saline solution, infusion, 250cc: 1.1 percent
- Ondansetron hydrochloride, per 1mg: 1.1 percent
- Denosumab, injection, 1mg: 1.1 percent
- Palonosetron HCL, injection, 25mcg: 1 percent
- Iron sucrose, injection, 1mg: 1 percent
- Methylprednisolone sodium succinate, injection, 125mg: 0.9 percent
- Ranibizumab, injection, 0.1mg: 0.8 percent
- Omalizumab, injection, 5mg: 0.8 percent
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
